Ligand Pharmaceuticals (LGND) EPS (Weighted Average and Diluted) Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Ligand Pharmaceuticals | 4.55 Bn | 3.77 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.19% |
| Dec 31, 2025 | 44.17% |
| Sep 30, 2025 | 73.06% |
| Jun 30, 2025 | -28.89% |
| Mar 31, 2025 | -8.64% |
| Dec 31, 2024 | -31.33% |
| Sep 30, 2024 | 13.60% |
| Jun 30, 2024 | -31.23% |
| Mar 31, 2024 | -31.42% |
| Dec 31, 2023 | 20.21% |
| Sep 30, 2023 | -17.19% |
| Jun 30, 2023 | -46.59% |
| Mar 31, 2023 | 5.84% |
| Dec 31, 2022 | 15.70% |
| Sep 30, 2022 | -27.52% |
| Jun 30, 2022 | -24.37% |
| Mar 31, 2022 | -19.34% |
| Dec 31, 2021 | -26.71% |
| Sep 30, 2021 | 88.50% |
| Jun 30, 2021 | 55.41% |
| Mar 31, 2021 | 34.49% |
| Dec 31, 2020 | 3.83% |
| Sep 30, 2020 | -15.39% |
| Jun 30, 2020 | 3.53% |
| Mar 31, 2020 | -107.54% |
| Dec 31, 2019 | -26.70% |
| Sep 30, 2019 | -73.01% |
| Jun 30, 2019 | -65.91% |
| Mar 31, 2019 | 215.62% |
| Dec 31, 2018 | -89.51% |
| Sep 30, 2018 | 98.88% |
| Jun 30, 2018 | 58.38% |
| Mar 31, 2018 | 92.07% |
| Dec 31, 2017 | -102.04% |
| Sep 30, 2017 | 209.06% |
| Jun 30, 2017 | 73.21% |
| Mar 31, 2017 | 619.68% |
| Sep 30, 2016 | 296.96% |
| Mar 31, 2016 | 330.10% |
| Dec 31, 2015 | 21.42% |
| Sep 30, 2015 | 585.89% |
| Jun 30, 2015 | 399.43% |